PuraPharm (HKSE:01498) Stock Based Compensation : HK$4.3 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is PuraPharm Stock Based Compensation?

PuraPharm's Stock Based Compensation for the six months ended in Dec. 2023 was HK$2.1 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 was HK$4.3 Mil.

PuraPharm Stock Based Compensation Historical Data

The historical data trend for PuraPharm's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PuraPharm Stock Based Compensation Chart

PuraPharm Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Stock Based Compensation

Get a 7-Day Free Trial

4.22

5.64

3.50

0.27

4.29

PuraPharm Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Stock Based Compensation	Get a 7-Day Free Trial															0.98	0.17	0.10	2.15	2.14

PuraPharm Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$4.3 Mil.

PuraPharm Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of PuraPharm's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

PuraPharm (HKSE:01498) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PuraPharm Corporation Ltd (HKSE:01498) » Definitions » Stock Based Compensation

Traded in Other Exchanges

N/A

Address

Wireless Centre, Phase One, Unit 201-207, 2nd Floor, Hong Kong Science Park, Tai Po, New Territories, Hong Kong, HKG

Website

https://www.purapharm.com

PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. In addition, the organization is engaged in rendering Chinese medical diagnostic services. The operating segments of the group are China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation and Clinics. It generates maximum revenue from the China CCMG segment mainly engages in the production and sale of CCMG products in China. The group derives revenue from the customers located in Hong Kong, Mainland China and Other countries.

PuraPharm (HKSE:01498) Headlines

No Headlines